Chronic hepatitis B: What should be the goal for new therapies?

Chronic hepatitis B can currently be medically managed with either pegylated interferon-alpha (pegIFN-α) or one of the five nucleos(t)ide analogue Direct Acting Antivirals (DAAs) that inhibit the hepatitis B virus (HBV) DNA polymerase. While pegIFN-α is effective in approximately one-third of the tr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Block, Timothy M., Gish, Robert, Guo, Haitao, Mehta, Anand, Cuconati, Andrea, London, W. Thomas, Guo, Ju-Tao
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627746/
https://ncbi.nlm.nih.gov/pubmed/23391846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2013.01.006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires